Caverject Shortage: What Providers and Prescribers Need to Know in 2026

The Caverject supply disruption that began in 2023 culminated in a significant market shift: in July 2025, Pfizer permanently discontinued the Caverject brand and transitioned to generic alprostadil equivalents. For prescribers managing patients who rely on intracavernosal alprostadil therapy, this creates immediate clinical and logistical challenges. Here is a comprehensive briefing on what happened, what the current landscape looks like, and how to best support your patients.

Timeline of the Caverject Supply Disruption

2023: Pfizer issues a formal supply alert. Caverject Dual Chamber faces stock-out; 40 mcg vials projected to be affected from June 2023, with recovery estimated by mid-2024. Root cause: manufacturing capacity diverted to another high-demand Pfizer product.

2024: Partial recovery for some vial strengths; Caverject Impulse and Dual Chamber remain inconsistently available. Many patients and practices report inability to reliably source the medication.

March 2025: Meitheal Pharmaceuticals launches Alprostadil Injection, USP 500 mcg/mL, adding supply capacity.

July 2025: Pfizer announces permanent discontinuation of the Caverject brand. Generic equivalents (alprostadil 10 mcg and 20 mcg injections) are released as replacements.

2026: Caverject brand is no longer manufactured. Generic alprostadil injection is the standard, but local pharmacy stocking remains inconsistent during the market transition.

Prescribing Implications: What You Need to Do

Update Existing Prescriptions

Prescriptions written for "Caverject" or "Caverject Impulse" by brand name may not be automatically substituted at all pharmacy systems, depending on state substitution laws and individual pharmacy software. Proactively reissue prescriptions for "alprostadil injection" (generic) or "Edex" (if Endo's brand is preferred) for patients who contact your office with filling difficulties.

Consider Transitioning Appropriate Patients to Trimix

Compounded Trimix (alprostadil 20 mcg/mL + papaverine 30 mg/mL + phentolamine 1–2 mg/mL) is often more clinically effective than alprostadil monotherapy and is associated with less post-injection pain. The effective dose volume of Trimix is approximately half that of alprostadil alone. For appropriate patients — particularly those who experienced significant pain with Caverject — this disruption is a natural opportunity to reconsider Trimix. Partner with a licensed compounding pharmacy you trust for this.

Counsel Patients on the Brand Transition

Many patients are not aware that Caverject brand has been discontinued. A proactive conversation — at the next visit or via a patient communication — will reduce confusion and panic when they attempt to refill. Key talking points:

Caverject brand is no longer manufactured, but generic alprostadil injection contains the same active ingredient at the same doses.

Their dose titrated to the brand will translate directly to the generic — no re-titration required in most cases.

They may need to contact a specialty or compounding pharmacy rather than their usual retail chain.

Insurance and Prior Authorization Considerations

Alprostadil products consistently require prior authorization from most major insurers including Cigna, BCBS, and Health Net. Authorization criteria typically include:

Documented diagnosis of erectile dysfunction

Trial and failure of (or contraindication to) oral PDE5 inhibitors

Post-radical prostatectomy patients may qualify for an accelerated pathway

If a patient's prior authorization was for Caverject brand, a new PA may be required when switching to generic alprostadil or Edex. Check with each insurer's formulary guidelines and be prepared to resubmit documentation.

Clinical Reminders for Intracavernosal Therapy

Initial dose titration must be performed in the office under medical supervision — advise patients that this applies to any new formulation or brand change.

Alprostadil maximum dose is 60 mcg (Edex: 40 mcg). Frequency should not exceed 3 times per week with at least 24 hours between doses.

Monitor for penile fibrosis — physical examination of the penis should be performed periodically. Discontinue therapy if angulation or cavernosal fibrosis develops.

Counsel patients that priapism (erection lasting >4 hours) requires immediate emergency care.

How medfinder Supports Your Patients

One practical tool you can share with patients: medfinder for providers. medfinder contacts pharmacies on the patient's behalf to find out which ones can fill their prescription. This removes a significant burden from your staff and gives patients a concrete action step when they're struggling to locate their medication.

See also: How to help your patients find Caverject in stock: A provider's guide.